Who are Tislelizumab, Cisplatin, Gemcitabine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine, Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tislelizumab-cisplatin-gemcitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Tislelizumab, Cisplatin, Gemcitabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tislelizumab, Cisplatin, Gemcitabine (Tislelizumab, Cisplatin, Gemcitabine) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor, platinum-based chemotherapy, nucleoside analog. Area: Oncology.

phase 3 PD-1 inhibitor, platinum-based chemotherapy, nucleoside analog PD-1, DNA Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Tislelizumab, Cisplatin, Gemcitabine (Tislelizumab, Cisplatin, Gemcitabine) — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Tislelizumab is a PD-1 inhibitor monoclonal antibody that blocks the PD-1 receptor, Cisplatin is a platinum-based chemotherapy drug that interferes with DNA replication, and Gemcitabine is a nucleoside analog that inhibits DNA synthesis.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tislelizumab, Cisplatin, Gemcitabine TARGET	Tislelizumab, Cisplatin, Gemcitabine	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	phase 3	PD-1 inhibitor, platinum-based chemotherapy, nucleoside analog	PD-1, DNA
Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine	Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine	RemeGen Co., Ltd.	phase 3	Combination therapy: antibody-drug conjugate, PD-1 inhibitor, platinum agent, and antimetabolite	HER2, PD-1, DNA (via oxaliplatin and capecitabine)
Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine	Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine	Sun Yat-sen University	phase 3	Combination therapy: EGFR inhibitor (monoclonal antibody), PD-1 inhibitor, platinum-based chemotherapy, nucleoside analog	EGFR (nimotuzumab), PD-1 (toripalimab), DNA (cisplatin and gemcitabine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor, platinum-based chemotherapy, nucleoside analog class)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tislelizumab, Cisplatin, Gemcitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/tislelizumab-cisplatin-gemcitabine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab